圣达生物: 浙江圣达生物药业股份有限公司2025年半年度报告摘要

Core Viewpoint - Zhejiang Sandar Biopharmaceutical Co., Ltd. reported significant growth in its financial performance for the first half of 2025, with notable increases in total assets, revenue, and net profit compared to the previous year [1]. Financial Performance - Total assets reached approximately CNY 2.11 billion, an increase of 18.43% from the end of the previous year [1]. - Operating revenue for the period was approximately CNY 400.73 million, reflecting a growth of 4.23% year-on-year [1]. - Total profit amounted to approximately CNY 50.27 million, representing a substantial increase of 107.77% compared to the same period last year [1]. - Net profit attributable to shareholders was approximately CNY 35.06 million, which is a remarkable increase of 580.57% year-on-year [1]. Shareholder Information - The total number of shareholders as of the reporting period was 17,587 [2]. - The largest shareholder, Zhejiang Sandar Group Co., Ltd., holds 24.00% of the shares, amounting to 45,375,792 shares [2]. - Other significant shareholders include Tian Tai Wan Jian Investment Development Center and Zhejiang Hongbo Enterprise Management Co., Ltd., holding 15.20% and 6.36% of shares, respectively [2].